

# Phathom<sup>®</sup>

## PHARMACEUTICALS

### **Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026**

April 20, 2026

- *Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT*

FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. A recording will be available for 90 days following the conclusion of the call.

#### **About Phathom Pharmaceuticals, Inc.**

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA<sup>®</sup> (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA<sup>®</sup> TRIPLE PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA<sup>®</sup> DUAL PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules) for the treatment of *H. pylori* infection in adults. For more information about Phathom, visit the company's website at [www.phathompharma.com](http://www.phathompharma.com) and follow on [LinkedIn](#) and [X](#).

#### **MEDIA CONTACT**

Nick Benedetto  
1-877-742-8466  
[media@phathompharma.com](mailto:media@phathompharma.com)

#### **INVESTOR CONTACT**

Eric Sciorilli  
1-877-742-8466  
[ir@phathompharma.com](mailto:ir@phathompharma.com)

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.